Suppr超能文献

欧洲泌尿外科学会上尿路尿路上皮癌指南:2020 年更新版。

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.

机构信息

Urology, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria.

出版信息

Eur Urol. 2021 Jan;79(1):62-79. doi: 10.1016/j.eururo.2020.05.042. Epub 2020 Jun 24.

Abstract

CONTEXT

The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice.

OBJECTIVE

To provide an overview of the EAU guidelines on UTUC as an aid to clinicians.

EVIDENCE ACQUISITION

The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract carcinoma, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, adjuvant treatment, instillation, recurrence, risk factors, and survival. References were weighted by a panel of experts.

EVIDENCE SYNTHESIS

Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification as well as for radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumour and two functional kidneys. After radical nephroureterectomy, cisplatin-based chemotherapy is indicated in locally advanced UTUC.

CONCLUSIONS

These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours.

PATIENT SUMMARY

Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.

摘要

背景

欧洲泌尿外科学会(EAU)上尿路上皮癌指南小组针对上尿路上皮癌(UTUC)制定了更新的指南,以帮助临床医生在当前基于证据的 UTUC 管理中,并将建议纳入临床实践。

目的

提供 EAU 关于 UTUC 的指南概述,以帮助临床医生。

证据获取

当前指南中的建议是基于对现有 UTUC 指南和系统搜索 Medline 后确定的文章的彻底审查。使用以下关键字搜索尿路上皮恶性肿瘤和 UTUC 的数据:尿路癌、尿路上皮癌、上尿路上皮癌、肾盂、输尿管、膀胱癌、化疗、输尿管镜检查、肾输尿管切除术、肿瘤、辅助治疗、灌注、复发、风险因素和生存。由专家组对参考文献进行加权。

证据综合

由于 UTUC 罕见,因此没有足够的数据提供强有力的建议。推荐使用 2017 年肿瘤、淋巴结、转移(TNM)分类。对诊断和风险分层以及根治性和保守性治疗提出了建议,并讨论了预后因素。肾输尿管切除术后单次膀胱内丝裂霉素灌注可降低膀胱癌复发的风险。对于低危肿瘤和两个功能肾脏的患者,应提供保肾管理作为主要治疗选择。根治性肾输尿管切除术后,局部晚期 UTUC 应采用顺铂为基础的化疗。

结论

这些指南包含了根据当前标准化方法管理个别患者的信息。泌尿科医生在确定最佳治疗方案时,应根据这些肿瘤的提出的风险分层,考虑到每位患者的具体临床特征。

患者总结

上尿路上皮癌罕见,但由于 60%的这些肿瘤在诊断时为浸润性,因此适当的诊断最为重要。存在一些已知的风险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验